Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…
Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
November 5-7, 2018 Copenhagen, Denmark Come meet IRBM’s delegates in Copenhagen to learn more about how IRBM can support your drug discovery efforts. Drop us a line to request a meeting through our contact form or, when open, the PartneringONE…
September 5-6, Boston, USA Our Global VP of Sales and Marketing, Heidi Kingdon-Jones, will join delegates from all over the world at Biopharm America in Boston. To meet with Heidi and learn about IRBM’s capabilities, reach out to us through…
4th September 2018
Pomezia, Italy – IRBM, today announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, known as MSD outside the United States and Canada, continuing their long-standing history of collaboration that began in 2010.
September 2-6, Ljubljana, Slovenia Our delegates, Dr. Jesus Maria Ontoria and Dr. Pier Giorgio Pacifici, will be attending the EFMC International Symposium of Medicinal Chemistry. If you’d like to learn more about what IRBM can do for your projects, or…
IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect. A liquid chromatography high-resolution…
June 4-7, 2018 Boston, MA, United States IRBM will be attending the BIO International conference in Boston, MA, from June 4 to June 7. To learn more about how IRBM can support your drug discovery efforts, drop us a line…
Pomezia, Italy, May 31, 2018 – IRBM, a global Contract Research Organization, has recruited two new members of staff as part of its global growth strategy. Carlo Toniatti, M.D., Ph.D., has been appointed as the Chief Scientific Officer, bringing more than two decades of drug development and discovery experience to the role where he will oversee scientific strategy, and Heidi Kingdon-Jones has been recruited as the Global VP of Sales and Marketing, to drive forward IRBM’s continued global expansion.
March 12 - 14, 2018 Amsterdam, The Netherlands Our own Matteo Liguori, Dr. Pier Giorgio Pacifici and Dr. Pierfausto Senecti will be attending BIO-Europe Spring in Amsterdam, from March 12 to March 14. To learn more about how IRBM can…